Summit Partners Public Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Summit Partners Public Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150,000	Closed	-$11.1M	–	167
2026 Q1	$11.1M	Buy	+150,000	New	+$10.9M	0.3%	89

Other funds holding BBIO

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Summit Partners Public Asset Management's BBIO Position: Q2 2026 in Review

Summit Partners Public Asset Management increased its BridgeBio Pharma (BBIO) stake by 76% in Q2 2026, buying an estimated $18.8M and bringing the position to 621,125 shares worth $46.3M. The position accounts for 0.81% of the portfolio, ranked #39.

Summit Partners Public Asset Management first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $62.2M in Q4 2025. 357 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Summit Partners Public Asset Management held 621,125 shares of BridgeBio Pharma worth $46.3M as of Q2 2026.
Summit Partners Public Asset Management bought 268,294 BridgeBio Pharma shares in Q2 2026, an estimated $18.8M.
BridgeBio Pharma made up 0.81% of Summit Partners Public Asset Management's portfolio in Q2 2026, its #39 holding.
Summit Partners Public Asset Management first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
Summit Partners Public Asset Management's BridgeBio Pharma position peaked at $62.2M in Q4 2025.
357 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.